NU 9056 |
Catalog No.GC11972 |
Selective KAT5 (Tip60) histone acetyltransferase inhibitor (IC50 values are < 2, 60, 36, and >100 μM for KAT5, p300, pCAF and GCN5, respectively).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1450644-28-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment [1]: | |
Specificity for Tip60 Acetyltransferase |
NU9056 was tested for in vitro activity against a panel of recombinant HAT enzymes, including p300, PCAF and GCN5, to determine whether it shows greater specificity towards Tip60. A number of compounds were found to inhibit the activity of Tip60 at low micromolar concentrations. However, specificity towards Tip60 over other HAT enzymes tested was found to be greatest with compound 7 (NU9056) as shown in Table 1 (16.5-, 29- and .50-fold for selectivity for Tip60 over PCAF, p300 and GCN5, respectively). |
Cell experiment [1]: | |
Cell lines |
LNCaP cells, PC3 cells, LNCaP-CdxR and CWR22rv1 cells |
Preparation method |
Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
2.5, 5, 10, 20, and 40 μM; 24, 48, 72 and 96 h |
Applications |
In LNCaP cells, NU9056 decreased levels of acetylated histone H4K16, H3K14 and H4K8, targets for Tip60-mediated acetylation. NU9056 inhibited cell growth with GI50 values of 24 μM and 27 μM for LNCaP and PC3 cells, respectively. LNCaP-CdxR and CWR22rv1 cells showed significantly greater sensitivity to NU9056 than the parental LNCaP cell line with GI50 values of 12 μM and 7.5 μM, respectively. The most sensitive cell line CWR22rv1 actually expressed the most Tip60. Treatment with NU9056 (24 μM) for 24h significantly reduced colony forming ability of LNCaP cells. In LNCaP cells, NU9056 also resulted in both caspase 3 and caspase 9 activation in a time- and concentration-dependent way, and induced apoptosis. |
References: [1] Coffey K1, Blackburn TJ, Cook S, et al. Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS One. 2012;7(10):e45539. |
Selective KAT5 (Tip60) histone acetyltransferase inhibitor (IC50 values are < 2, 60, 36, and >100 μM for KAT5, p300, pCAF and GCN5, respectively). Inhibits protein acetylation in prostate cancer cell lines and blocks DNA damage response. Decreases proliferation of LNCaP cells; induces apoptosis via caspase activation.
Cas No. | 1450644-28-6 | SDF | |
Chemical Name | 1,2-di(isothiazol-5-yl)disulfane | ||
Canonical SMILES | C1(SSC2=CC=NS2)=CC=NS1 | ||
Formula | C6H4N2S4 | M.Wt | 232.37 |
Solubility | <10mg/ml in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.3035 mL | 21.5174 mL | 43.0348 mL |
5 mM | 0.8607 mL | 4.3035 mL | 8.607 mL |
10 mM | 0.4303 mL | 2.1517 mL | 4.3035 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *